Science Translational Medicine (@ScienceTM) header
Science Translational Medicine (@ScienceTM) profile picture

Science Translational Medicine

@ScienceTM

Science Translational Medicine is the leading weekly online journal publishing translational research at the intersection of science, engineering and medicine.

 Washington, DC
science.org/journal/stm
Joined February 2011
  • Tweets4K
  • Following269
  • Followers35.3K
A #pharmacogenomics analysis of 100,000 participants in the @AllofUsResearch program sheds light on the landscape of pharmacogene variants in diverse ancestries and tackles gaps in genomics knowledge in underrepresented groups. @philempey @pittpharmacy scim.ag/4t0sL1S
Pie chart displaying ancestry percentages: European 49.03%, African 23.39%, Americas 15.28%, Remaining 9.00%, East Asian 2.15%, South Asian 0.98%, and Middle Eastern 0.17%.

ALT Pie chart displaying ancestry percentages: European 49.03%, African 23.39%, Americas 15.28%, Remaining 9.00%, East Asian 2.15%, South Asian 0.98%, and Middle Eastern 0.17%.

1
1
256
A study of 100,000 diverse Americans tackles gaps in pharmacogenomics representation, scientists connect sleep-like slow brain waves to hallucinations and poorer cognition in Parkinson’s disease, and more this week in #ScienceTranslationalMedicine. scim.ag/48Lwery
Image from Science Translational Medicine (@ScienceTM)
3
12
7,263
By comparing PET scans between patients with early-onset and late-onset #AlzheimersDisease, researchers uncover key differences in tauopathy between the age groups that could inform future diagnostics and therapeutics. @UCSFmac scim.ag/4z9byVl
Image from Science Translational Medicine (@ScienceTM)
1
5
12
1,150
How well does #VRC01 protect against #HIV? An analysis of the post-infusion period in two clinical trials shows that prophylaxis blocks infections with sensitive strains but that breakthrough infections still occur after infusions stopped. @fredhutch scim.ag/4elPMWL
Image from Science Translational Medicine (@ScienceTM)
3
5
1,185
A triplet combination therapy based on first-line #regorafenib remodels the tumor microenvironment in patients with advanced #GastricCancer while displaying promising safety and response rate, according to a new phase 2 clinical trial. @NccriOfficial scim.ag/4Agt1vJ
Image from Science Translational Medicine (@ScienceTM)
3
13
1,491
In a unique human challenge study, researchers interrogate how preexisting immunity and antibodies against the four serotypes of #dengue influence viremia, T cell responses, and immune activation in a safe and controlled setting. @CamilaOdio @NIH scim.ag/3W4jxVS
Image from Science Translational Medicine (@ScienceTM)
1
2
6
1,309
By analyzing a massive collection of #TcellReceptor chains from 150,000+ patient samples, researchers develop a pipeline to accelerate the discovery and validation of public T cell receptors for immunotherapeutic design. @BioNTech_Group scim.ag/48BezCN
Image from Science Translational Medicine (@ScienceTM)
2
3
13
1,338
Clinical trials of an anti-HIV antibody offer clues to prevent viral escape and resistance, a massive dataset accelerates the discovery of T cell receptors for future cancer therapeutics, and more this week in #ScienceTranslationalMedicine. scim.ag/4sGXxwj
Image from Science Translational Medicine (@ScienceTM)
2
5
18
8,254
A new analysis of mice and samples from patients with #psoriasis identifies CHI3L2 as a central driver of the condition, showing that it propels an inflammatory loop by reprogramming phospholipid metabolism in keratinocytes. @XJTU_China scim.ag/4yYjMzC
Image from Science Translational Medicine (@ScienceTM)
1
1
7
1,059
New work links synovial inflammation in #osteoarthritis to a signaling axis involving CD74 and ENO2 that reprograms macrophages into an inflammatory and metabolically active state—but shows these cells can be targeted to treat the disease in mice. scim.ag/4A4r7yx
Image from Science Translational Medicine (@ScienceTM)
2
2
4
1,035
By applying a unique polyene scaffold, researchers engineer a next-generation, broad-spectrum #antifungal that selectively targets ergosterol without binding to cholesterol, avoiding severe toxicity linked to drugs like amphotericin B. scim.ag/4yyYZSP
Image from Science Translational Medicine (@ScienceTM)
2
3
1,241
A new bispecific antibody targets both #CCR8 to deplete regulatory T cells and CD3 to revitalize the broader anti-tumor T cell armada. It combated multiple tumor types and potentiated immunotherapy in mice while being safe in large animals. @genentech scim.ag/4e4t05H
Image from Science Translational Medicine (@ScienceTM)
3
19
1
105
6,197
In a unique human challenge study, researchers interrogate how preexisting immunity and antibodies against the four serotypes of #dengue influence viremia, T cell responses, and immune activation in a safe and controlled setting. @CamilaOdio @NIH scim.ag/3W4jxVS
Image from Science Translational Medicine (@ScienceTM)
4
7
1,128
A unique human challenge study illuminates how dengue immunity shapes the nature of repeated infections, researchers identify a targetable molecular driver of skin inflammation in psoriasis, and more this week in #ScienceTranslationalMedicine. scim.ag/4zgXqds
Image from Science Translational Medicine (@ScienceTM)
1
3
22
7,879
By applying a unique polyene scaffold, researchers engineer a next-generation, broad-spectrum #antifungal that selectively targets ergosterol without binding to cholesterol, avoiding severe toxicity linked to drugs like amphotericin B. scim.ag/4yyYZSP
Image from Science Translational Medicine (@ScienceTM)
3
735
Researchers present a novel agent for near-infrared fluorescent imaging of #LungCancer that binds to ChoK-alpha, which can highlight close tumor margins and spot easy-to-miss lesions during surgical resection of tumors in canines. @PennRadiology scim.ag/4hVPF6z
A fluorescent choline kinase alpha inhibitor for intraoperative molecular imaging during resection...

A fluorescent choline kinase alpha inhibitor for intraoperative molecular imaging during resection...

A near-infrared fluorescent choline kinase α inhibitor, JAS239, was used to identify tumors in canine patients.

science.org
1
2
1,114
By parsing metabolic data from more than 18,000 participants in China, scientists have derived new “clock” models of metabolic #aging that incorporate novel metrics linked to higher chronic disease risk and all-cause mortality. @sjtu1896 scim.ag/4zzZLzU
A person rides a bicycle on a flat surface. The shadow cast on an orange background shows the person on a larger bicycle with clock faces as wheels.

ALT A person rides a bicycle on a flat surface. The shadow cast on an orange background shows the person on a larger bicycle with clock faces as wheels.

2
1
871
An analysis of trial data from stem cell transplant recipients shows how immune suppression with either #cyclophosphamide or #tacrolimus shapes T cell reconstitution—and has opposing effects on the risk of #GVHD or infection post-transplant. @MSK_DeptOfMed scim.ag/4k8Is4p
Image from Science Translational Medicine (@ScienceTM)
3
2
761
By applying a unique polyene scaffold, researchers engineer a next-generation, broad-spectrum #antifungal that selectively targets ergosterol without binding to cholesterol, avoiding severe toxicity linked to drugs like amphotericin B. scim.ag/4yyYZSP
Image from Science Translational Medicine (@ScienceTM)
2
3
579
A new antifungal drug architecture combats infections in mice without the usual toxicity, a fluorescent imaging agent could enable more pinpointed removal of lung cancer tumors, and more in this week's new issue of #ScienceTranslationalMedicine. scim.ag/4z2AYEQ
Successful hematopoietic cell transplantation (HCT) requires immunosuppression to prevent graft-versus-host disease (GVHD), but the choice of regimen may shape immune reconstitution and GVHD risk. DeWolf et al. analyzed the T cell repertoires of clinical trial participants who received either tacrolimus and methotrexate (Tac/MTX) or posttransplant cyclophosphamide, mycophenolate mofetil, and tacrolimus (PT-Cy) as GVHD prophylaxis after HCT. PT-Cy more profoundly depleted the T cell compartment, creating a bottleneck as depicted on the cover, which resulted in a less diverse T cell repertoire. This reduced diversity was associated with lower GVHD risk but higher risk of infection after transplant. These findings show that immunosuppressive regimens can shape the balance between beneficial and harmful outcomes of HCT. Credit: N. Burgess/Science Translational Medicine

ALT Successful hematopoietic cell transplantation (HCT) requires immunosuppression to prevent graft-versus-host disease (GVHD), but the choice of regimen may shape immune reconstitution and GVHD risk. DeWolf et al. analyzed the T cell repertoires of clinical trial participants who received either tacrolimus and methotrexate (Tac/MTX) or posttransplant cyclophosphamide, mycophenolate mofetil, and tacrolimus (PT-Cy) as GVHD prophylaxis after HCT. PT-Cy more profoundly depleted the T cell compartment, creating a bottleneck as depicted on the cover, which resulted in a less diverse T cell repertoire. This reduced diversity was associated with lower GVHD risk but higher risk of infection after transplant. These findings show that immunosuppressive regimens can shape the balance between beneficial and harmful outcomes of HCT. Credit: N. Burgess/Science Translational Medicine

1
6
22
7,694
Load more